阿替洛尔在持续性非卧床腹膜透析患者中的药代动力学
Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
作者信息
Salahudeen A K, Wilkinson R, McAinsh J, Bateman D N
出版信息
Br J Clin Pharmacol. 1984 Sep;18(3):457-60. doi: 10.1111/j.1365-2125.1984.tb02490.x.
Abstract
The elimination of atenolol (20 mg i.v.) has been studied in seven patients with renal failure on continuous ambulatory peritoneal dialysis (CAPD). Although atenolol was eliminated in the peritoneal fluid, the amount recovered in 24 h was relatively low (1.2 +/- 0.15 mg). The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively. This was considerably less than calculated total body clearance (1.21 +/- 0.086 l/h). The kinetics of atenolol in CAPD are worthy of further study.
摘要
对7例持续非卧床腹膜透析（CAPD）的肾衰竭患者进行了阿替洛尔（静脉注射20毫克）消除情况的研究。尽管阿替洛尔可在腹膜液中消除，但24小时内回收的量相对较低（1.2±0.15毫克）。计算得出的尿清除率（n = 4）和腹膜清除率（n = 7）分别为0.289±0.058升/小时和0.152±0.018升/小时。这远低于计算得出的总体清除率（1.21±0.086升/小时）。阿替洛尔在CAPD中的药代动力学值得进一步研究。
相似文献
1
Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.阿替洛尔在持续性非卧床腹膜透析患者中的药代动力学
Br J Clin Pharmacol. 1984 Sep;18(3):457-60. doi: 10.1111/j.1365-2125.1984.tb02490.x.
2
Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.阿替洛尔在持续腹膜透析兔体内的药代动力学和药效学建模。
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):41-8. doi: 10.1007/BF03189860.
3
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.奥硝唑在肾功能不全患者中的药代动力学；血液透析和腹膜透析的影响。
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
4
Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析中奎尼丁的药代动力学
Clin Exp Dial Apheresis. 1981;5(4):391-7. doi: 10.3109/08860228109076030.
5
Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者替考拉宁的药代动力学
Eur J Clin Pharmacol. 1986;31(4):501-4. doi: 10.1007/BF00613532.
6
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.阿替洛尔在终末期肾衰竭患者中的药代动力学及血液透析的影响。
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
7
Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者的阿昔洛韦药代动力学
Am J Kidney Dis. 1986 Jun;7(6):507-10. doi: 10.1016/s0272-6386(86)80193-7.
8
9
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析的慢性肾衰竭患者腹腔注射替考拉宁的药代动力学
Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x.
10
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.
引用本文的文献
1
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.体外治疗β-肾上腺素能拮抗剂中毒：EXTRIP 工作组的系统评价和建议。
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
2
Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.阿替洛尔在持续腹膜透析兔体内的药代动力学和药效学建模。
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):41-8. doi: 10.1007/BF03189860.
3
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析的慢性肾衰竭患者腹腔注射替考拉宁的药代动力学
Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x.
4
Teicoplanin pharmacokinetics in patients with chronic renal failure.替考拉宁在慢性肾衰竭患者中的药代动力学
Clin Pharmacokinet. 1987 Apr;12(4):292-301. doi: 10.2165/00003088-198712040-00003.
5
Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者替考拉宁的药代动力学
Eur J Clin Pharmacol. 1986;31(4):501-4. doi: 10.1007/BF00613532.
6
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.阿替洛尔：对其药理特性及在心血管疾病治疗应用的重新评估
Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007.
本文引用的文献
1
Atenolol kinetics in renal failure.阿替洛尔在肾衰竭中的动力学
Clin Pharmacol Ther. 1980 Sep;28(3):302-9. doi: 10.1038/clpt.1980.166.
2
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.阿替洛尔在终末期肾衰竭患者中的药代动力学及血液透析的影响。
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
3
The pharmacokinetics of single doses of metoclopramide in renal failure.单剂量胃复安在肾衰竭患者中的药代动力学。
Eur J Clin Pharmacol. 1981;19(6):437-41. doi: 10.1007/BF00548588.
4
Kinetics and absolute bioavailability of atenolol.阿替洛尔的动力学与绝对生物利用度。
Clin Pharmacol Ther. 1979 Apr;25(4):408-15. doi: 10.1002/cpt1979254408.
5
The gas chromatographic determination of atenolol in biological samples.生物样品中阿替洛尔的气相色谱测定法。
J Pharm Pharmacol. 1975 Jun;27(6):430-3. doi: 10.1111/j.2042-7158.1975.tb09473.x.
6
Metabolism of atenolol in man.
Xenobiotica. 1978 May;8(5):313-20. doi: 10.3109/00498257809060956.
Zotero 插件